Edison Investment Research - Pharmaceutical & healthcare - MagForce: MagForce has received IDE approval to start its first pivotal clinical trial evaluating NanoTherm focal ablation therapy for prostate cancer in the US. This is a major milestone for the company. Prostate cancer in the US presents a significant market opportunity (representing ~60% of our rNPV) and makes sense strategically as a first US indication. The start of this trial will broaden the geographic and therapeutic reach of NanoTherm therapy beyond Europe, where it is already approved for brain cancer. Our updated valuation is €302.6m.
ISIN: DE000A0HGQF5
Original Article: MagForce (MF6) - US NanoTherm IDE approval a major milestone